Economic information and modeling reportBudget impact modelResults
Base case
1 evidence topic · 1 source
Modeled 24-month costs
| Outcome | Quoted value |
|---|---|
| Net health-system cost | “€4,371,005” |
| Savings versus financing without risk sharing | “€586,495” |
Saroglitazar
Primary biliary cholangitis
- Manufacturer
- Zydus Therapeutics
- Regulatory submission
- NDA submitted by May 2026
- Last updated